Invitrogen Corporation (Nasdaq:IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced the formation of Biological Defense Systems(TM) Inc. (BDS), a new venture that will consolidate and expand the company's biosecurity applications, leveraging products and knowledge gained through the company's long-standing efforts in pathogen research. Headquartered on Invitrogen's Frederick, Md. campus, BDS will operate as a wholly owned subsidiary, drawing upon Invitrogen's vast portfolio of products and services.
